You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 12, 2025

Claims for Patent: 12,458,634

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 12,458,634

Title:	Stabilized liquid formations containing picosulfate
Abstract:	Oral liquid formulations are provided containing sodium picosulfate, magnesium citrate, citric acid, malic acid, and an antioxidant selected from potassium metabisulfite and sodium metabisulfite, wherein the antioxidant is present in the composition at a concentration of from about 0.002 M to about 0.1 M, and wherein the composition has a pH of from about 4.0 to about 6.5.
Inventor(s):	Alfred Chi-Yeh Liang, Nipul Ghanshyambhai Patel
Assignee:	Ferring BV
Application Number:	US17/555,277
Patent Claims:	1. An oral, liquid pharmaceutical composition comprising: sodium picosulfate, magnesium oxide, citric acid, malic acid, and an antioxidant selected from potassium metabisulfite and sodium metabisulfite; wherein the antioxidant is present in the composition at a concentration of from about 0.002 M to about 0.1 M, and wherein the composition has a pH of from about 4.0 to about 6.5. 2. The composition of claim 1, wherein: the sodium picosulfate is present in the composition at a concentration of from about 0.10 mM to about 0.15 mM; the composition comprises magnesium and citrate in a molar ratio of from about 1:1 to about 1.5:1; the magnesium is present in the composition at a concentration of from about 0.2 M to about 0.8 M; the malic acid is present in the composition at a concentration in a range from about 0.01 M to about 5 M; and the antioxidant comprises sodium metabisulfite. 3. The composition of claim 1, wherein: the sodium picosulfate is present in the composition at a concentration of from about 0.12 mM to about 0.14 mM; the composition comprises magnesium and citrate in a molar ratio of about 1.4:1; the magnesium is present in the composition at a concentration of from about 0.5 M to about 0.6 M; the malic acid is present in the composition at a concentration in a range from about 0.1 M to about 1 M; and the antioxidant comprises sodium metabisulfite which is present in the composition at a concentration of from about 0.005 M to about 0.02 M. 4. The composition of claim 1, wherein the magnesium oxide and citric acid form magnesium citrate. 5. The composition of claim 1, further comprising a preservative agent selected from sodium benzoate and potassium benzoate. 6. The composition of claim 1, further comprising a chelating agent comprising disodium edetate (ETDA). 7. The composition of claim 1, wherein the composition has a pH of from about 4.5 to about 5.2. 8. The composition of claim 1, wherein the composition has a pH of from about 4.7 to about 4.9. 9. The composition of claim 1, wherein the composition has a pH of about 4.9. 10. The composition of claim 1, wherein, after storage for 1 year at a temperature of about 25° C. and about 60% relative humidity, the composition contains about 0.2% or less of Compound RRT 1.35, as measured by HPLC analysis area percentage relative to sodium picosulfate. 11. The composition of claim 1, wherein, after storage for 1 year at a temperature of about 25° C. and about 60% relative humidity, the composition contains about 0.1% or less of Compound RRT 1.35, as measured by HPLC analysis area percentage relative to sodium picosulfate. 12. The composition of claim 1, wherein, after storage for 1 year at a temperature of about 25° C. and about 60% relative humidity, the composition contains about 0.2% or less of Compound RRT 1.94, as measured by HPLC analysis area percentage relative to sodium picosulfate. 13. The composition of claim 1, wherein, after storage for 1 year at a temperature of about 25° C. and about 60% relative humidity, the composition contains about 0.1% or less of Compound RRT 1.94, as measured by HPLC analysis area percentage relative to sodium picosulfate. 14. The composition of claim 1, wherein, after storage for 1 year at a temperature of about 25° C. and about 60% relative humidity, the composition contains about 0.2% or less of Compound RRT 1.35 and about 0.2% or less of Compound RRT 1.94, as measured by HPLC analysis area percentage relative to sodium picosulfate. 15. The composition of claim 1, wherein, after storage for 1 year at a temperature of about 25° C. and about 60% relative humidity, the composition comprises less than about 1.5% Picosulfate Benzyl Alcohol, less than about 0.2% of Compound RRT 1.35, less than about 0.2% of Compound RRT 1.94, and less than about 1.5% of Picosulfate Related Compound A, as measured by HPLC analysis area percentage relative to sodium picosulfate.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.